Johnson & Johnson (JNJ) is a good quality business scoring 71/100, with particular strength in competitive moat and capital allocation. The business has solid fundamentals but falls short of elite quality on some measures.
Johnson & Johnson shows a solid competitive position with solid gross margins of 67.6%. However, some vulnerability to competitive pressure suggests the moat, while present, may face challenges. The business earns above-average returns but lacks the exceptional durability of the strongest moats.
Johnson & Johnson has limited pricing power. The company operates with margins that are average for its industry, and revenue growth has come with some margin pressure. This suggests the business competes partially on price rather than on differentiated value.
Johnson & Johnson offers good predictability. Revenue and cash flows have followed a generally consistent pattern over recent years. Though it experienced a 6.5% revenue dip at one point, the overall trajectory remains positive. The business model produces reasonably forecastable results.
Johnson & Johnson has a moderate financial position. Leverage is elevated but not critical. The balance sheet could face stress in an economic downturn. Management should prioritize debt reduction to strengthen the company's resilience.
Johnson & Johnson demonstrates excellent capital allocation, generating excellent returns on invested capital while reducing shares outstanding through buybacks. Management deploys capital at rates well above the cost of capital, creating significant value for shareholders.
The allocation between reinvestment, buybacks, and dividends appears disciplined and shareholder-friendly.
Johnson & Johnson's management team demonstrates strong execution, with stock-based compensation kept to just 1.3% of revenue. Consistent high returns on capital and stable operating margins indicate a team focused on operational excellence and long-term value creation rather than short-term metrics.

Predicted probability of operating margin improvement over the next 12 months
Johnson & Johnson est-elle un bon investissement à $239 ?
L'analyse suivante est fournie à des fins d'information et d'éducation uniquement. Elle ne constitue pas un conseil financier, un conseil en investissement ou une recommandation d'achat ou de vente de titres. Les opinions exprimées sont basées sur des informations publiques et des données historiques. Beanvest et ses contributeurs peuvent détenir des positions dans les titres mentionnés. Les investisseurs doivent effectuer leur propre diligence raisonnable ou consulter un conseiller financier agréé avant de prendre toute décision d'investissement.